Vanderbilt fills an R&D void left by Big Pharma cutbacks

While Big Pharma companies have been chopping at their own R&D shops while looking more often to outside academic experts to help them find the next blockbuster drug, Vanderbilt University has capitalized on the trend. Inking big deals with pharma giants Bristol-Myers Squibb ($BMY) and AstraZeneca ($AZN), Vanderbilt has emerged as a leading institution for central nervous system drug research and discovery by bringing a business-like approach to the lab. The announcement of Vanderbilt's latest partnership with AstraZeneca to develop drugs for brain diseases like Alzheimer's and schizophrenia comes only months after Vanderbilt said it would collaborate with Bristol-Myers to cultivate new therapies for Parkinson's disease. FierceBiotechResearch

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.